CLINICAL TRIALS PROFILE FOR ABLAVAR

All Clinical Trials for ABLAVAR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00375830 ↗	Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases	Completed	Stanford University	Phase 2	2006-01-01	This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer.
NCT01135316 ↗	Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR	Completed	Lantheus Medical Imaging		2009-10-01	Phase 4, open-label, two-year, prospective, multi-center, follow-up study conducted at up 15 sites in USA. Approximately 1,000 patients with moderate-to-severe CKD will be enrolled and followed for up to 24 months.
NCT01165892 ↗	Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar)	Completed	Lantheus Medical Imaging		2011-07-01	The use of the contrast agent, Ablavar, will help with the diagnosis of pulmonary embolism in magnetic resonance imaging (MRI).
NCT01165892 ↗	Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar)	Completed	Washington University School of Medicine		2011-07-01	The use of the contrast agent, Ablavar, will help with the diagnosis of pulmonary embolism in magnetic resonance imaging (MRI).
NCT01431300 ↗	Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants	Completed	Lantheus Medical Imaging	N/A	2011-08-01	The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography of the central veins of the chest, and to determine whether dose reduction can be performed while maintaining image quality. This will be a prospective randomized study, in which healthy volunteers will be recruited to undergo a central veins magnetic resonance angiogram (MRA). They will receive either the FDA-approved dose or a lower dose of Ablavar. Quantitative and qualitative analysis will be performed on the images.
NCT01431300 ↗	Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants	Completed	Duke University	N/A	2011-08-01	The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography of the central veins of the chest, and to determine whether dose reduction can be performed while maintaining image quality. This will be a prospective randomized study, in which healthy volunteers will be recruited to undergo a central veins magnetic resonance angiogram (MRA). They will receive either the FDA-approved dose or a lower dose of Ablavar. Quantitative and qualitative analysis will be performed on the images.

Clinical Trial Conditions for ABLAVAR

Condition Name

Condition Name for ABLAVAR
Intervention	Trials
Magnetic Resonance Imaging	1
Myocardial Ischemia	1
Neoplasms Staging	1
Nephrogenic Systemic Fibrosis	1

Condition MeSH

Condition MeSH for ABLAVAR
Intervention	Trials
Embolism	1
Neoplasms	1
Nephrogenic Fibrosing Dermopathy	1
Myocardial Ischemia	1

Clinical Trial Locations for ABLAVAR

Trials by Country

Trials by Country for ABLAVAR
Location	Trials
United States	6
Netherlands	6

Trials by US State

Trials by US State for ABLAVAR
Location	Trials
North Carolina	2
California	2
Illinois	1
New York	1

Clinical Trial Progress for ABLAVAR

Clinical Trial Phase

Clinical Trial Phase for ABLAVAR
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	2
N/A	2

Clinical Trial Status

Clinical Trial Status for ABLAVAR
Clinical Trial Phase	Trials
Completed	6
Recruiting	1
Terminated	1

Clinical Trial Sponsors for ABLAVAR

Sponsor Name

Sponsor Name for ABLAVAR
Sponsor	Trials
Maastricht University Medical Center	3
Lantheus Medical Imaging	3
Astellas Pharma Global Development, Inc.	1

Sponsor Type

Sponsor Type for ABLAVAR
Sponsor	Trials
Other	9
Industry	4